Taken together, the above results suggest that KLF2 is highly correlated with the immune microenvironment in HCC, and advanced HCC patients with lower KLF2 expression derive greater benefit from ICIs treatments. This evidence concerns the gene KLF2 and hepatocellular carcinoma.